(April 12, 2024, 2:22 PM EDT) -- WASHINGTON, D.C. — A final judgment by a federal judge in Delaware directing the U.S. Food and Drug Administration to delay approval of generic rifaximin until three patents covering the antibiotic Xifaxan expire was affirmed April 11 by a three-judge panel of the Federal Circuit U.S. Court of Appeals....